Tirzepatide is the active ingredient in two FDA-approved products, marketed as Mounjaro and Zepbound. When you see it offered as a compounded medication, you are looking at a different supply route with a different legal footing. Understanding that difference is the first step in comparing providers honestly.
The regulatory picture changed
During 2023 and much of 2024, tirzepatide sat on the FDA drug shortage list. That status opened a legal path for compounding pharmacies to prepare tirzepatide formulations, because federal law allows compounding of a drug in shortage under specific conditions. In October 2024 the FDA declared the tirzepatide shortage resolved.
That declaration matters. Once a drug is no longer in shortage, the legal basis for compounding a copy of it narrows significantly. Compounding is still permitted in limited circumstances, such as when a formulation is clinically different for an individual patient, but the broad availability seen during the shortage is not the same environment anymore. Any provider offering compounded tirzepatide today should be able to explain the legal basis for doing so.
Two kinds of compounding pharmacies
Compounded medications in the United States come from two categories of facility. A 503A pharmacy prepares medications for individual patients based on a prescription. A 503B outsourcing facility operates under stricter federal oversight and can produce larger batches. The distinction affects testing, labeling, and inspection standards.
When you compare providers, ask which type of pharmacy fills the prescription and whether that pharmacy is licensed in your state. This is a concrete, verifiable detail, not a marketing point.
What drives the cost
Price differences between providers usually reflect more than the drug itself. The visit fee for the prescribing clinician, whether visits are one time or recurring, the pharmacy's pricing, shipping, and any bundled follow-up all feed into the number you see advertised. Some telehealth models charge a flat monthly fee that folds several of these together, which can make direct comparison harder.
Brand-name tirzepatide is priced by its manufacturer and may be affected by insurance coverage and manufacturer savings programs. Compounded versions are priced independently. A lower sticker price is not automatically a better deal if it comes with less oversight or unclear sourcing.
How to vet a provider
Focus on questions with checkable answers rather than promises about results.
- Is there a real prescribing relationship with a licensed clinician, including a way to reach that clinician with questions?
- Which pharmacy fills the prescription, and is it licensed in your state?
- Can the provider explain the current legal basis for any compounded formulation they offer?
- Is pricing itemized so you can see what the visit, the medication, and follow-up each cost?
- What happens if you have a side effect or want to stop?
A provider that answers these plainly is easier to trust than one that leads with weight-loss testimonials. Marketing claims about outcomes are not something you can verify, and this article makes none.
The bottom line
Tirzepatide is a legitimate, FDA-approved drug, but the compounded market around it shifted once the shortage was declared resolved. Treat the legal basis, the licensing of the pharmacy, and transparent pricing as your baseline for comparing any provider. For decisions about whether tirzepatide fits your situation, talk with a licensed clinician who can review your full history. This article is general information, not medical advice.